Stockreport

Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Kyntra Bio, Inc.  (KYNB) 
PDF Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) [Read more]